ArticleOncotarget2017
Prognostic significance of PD-L1 expression and
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.Thoracic cancer · 2020Pooled it
- Standardized Uptake Values Derived fromContrast media & molecular imaging · 2018Pooled it
- PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis.Scientific reports · 2017Pooled it
- The predictive value of total body PET/CT in high PD-L1 expression and immunotherapy in advanced non-small cell lung cancer patients.Frontiers in oncology · 2025Article
- The relationship between sarcopenia and metabolic parameters ofQuantitative imaging in medicine and surgery · 2024Article
- The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.Japanese journal of radiology · 2024Review
- Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma.Journal of the Korean Society of Radiology · 2024Article
- Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment.International journal of molecular sciences · 2022Review
- Prospective assessment usingScientific reports · 2022Article
- The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression.Frontiers in oncology · 2022Article
- Clinical imaging of primary pulmonary nucleoprotein of the testis carcinoma.Frontiers in medicine · 2022Article
- Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer.Frontiers in medicine · 2022Article
- Tumor immunity is related toCancer medicine · 2021Article
- Imaging Assessment of Tumor Response in the Era of Immunotherapy.Diagnostics (Basel, Switzerland) · 2021Review
- Association betweenThe British journal of radiology · 2021Article
- Value ofCancer imaging : the official publication of the International Cancer Imaging Society · 2021Review
- Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study.Frontiers in oncology · 2021Article
- Correlation Between Dual-Time-Point FDG PET and Tumor Microenvironment Immune Types in Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Article
- PD-L1 as a prognostic biomarker in surgically resectable non-small cell lung cancer: a meta-analysis.Translational lung cancer research · 2020Article
- Relationship Between Tumor Immune Markers and Fluorine-18-α-Methyltyrosine ([Molecular imaging and biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed cell death-ligand 1 (PD-L1) expression is commonly observed in non-small cell lung cancer (NSCLC). The prognostic value of PD-L1 expression and the maximum standardized uptake value (SUVmax) on 18F-Fluorodeoxyglucose positron emission tomography (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.